Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RET | P07949 | 7/20 | 0.41 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.35 |
| ▸ | PDE9A | O76083 | 1/20 | 0.35 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.33 |
| ▸ | HPGDS | O60760 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22031262 | 0.86 | RET (0.42) | RETCHRM1PDE9AHDAC6 | |
| SCHEMBL20148690 | 0.83 | RET (0.44) | RETCHRM1PDE9AHDAC6HPGDS | |
| SCHEMBL20070777 | 0.83 | RET (0.40) | RETCHRM1PDE9AHDAC6 | |
| SCHEMBL22031263 | 0.83 | RET (0.40) | RETCHRM1PDE9AHDAC6 | |
| SCHEMBL23126262 | 0.81 | CYP11B1 (0.40) | RET | |
| SCHEMBL20154478 | 0.79 | RET (0.42) | RET | |
| SCHEMBL18390929 | 0.79 | RET (0.47) | RET | |
| SCHEMBL18390322 | 0.77 | ALDH1A1 (0.51) | RETKMT2A | |
| SCHEMBL18713233 | 0.74 | CHRNB2 (0.49) | RET | |
| SCHEMBL22030585 | 0.71 | RET (0.46) | RET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10172851-B2 | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2019-01-08 | — | — | US | disclosed |
| US-20180133213-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA INC. | 2018-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10172851-B2 | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors | RET, ROR1, BRAF | RET 1/4885CHRM1 2284/4885PDE9A 791/4885 |
| US-20180133213-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | RET, ROR1, BRAF | RET 1/4885CHRM1 2284/4885PDE9A 791/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.